Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay
Pfizer plans to let the biotech drug developer continue innovating, except with more resources. Seagen's key products use monoclonal antibodies that help deliver a cancer-killing drug while sparing surrounding tissue.
Pfizer Inc PFE.N struck a $43 billion deal for Seagen Inc SGEN.O to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers. Monday's deal, Pfizer's biggest in a string of acquisitions following a once-in-a-lifetime cash windfall…